Table 1.

Expression of leptin/OB-R in breast cancer.

Breast cancer	Subtype	Leptin	OB-R	Techniques	Reference
Carcinoma		92%	83%	IHC	Ishikawa et al. (2004)
	DICa (80%; n = 417/517)	39% (p = 0.02)b	79%	IHC	Kim (2009)
	24% of TNBC		(p = 0.05)b
	No TNBC	36%	80%	IHC	Kim (2009)
	Normal BMI	43%	74%	IHC	Kim (2009)
	Overweight/obese	37%	85%	IHC	Kim (2009)
	Primary tumor	86%	41%	IHC	Garofalo et al. (2006)
	Metastasis	94%	52%	IHC	Garofalo et al. (2006)
	Diverse subtypes (n = 322)	99%	100%	Real-time RT-PCR	Revillion et al. (2006)
	Diverse subtypes (n = 20)		100%	Real-time RT-PCR	Laud (2002)
Cell lines
Human	MCF-7	2.6 pg/ml/mg	(+)	ELISA, WB	Rene Gonzalez et al. (2009)
		(0.15 pM)c
	MDA-MB-231	9.6 pg/ml/mg	(+)
		(0.41 pM)c
	MCF-7		(+)	IHC; real-time RT-PCR; in situ hybridization	Laud (2002) and Cascio (2008)
	MDA-MB231	10 pg/ml c	(+)	IHC, real-time RT-PCR	Soma (2008) and Bartella et al. (2008)
	SKBR-3		(+)	IHC	Soma (2008)
	T47D		(+)	IHC; real-time RT-PCR; in situ hybridization	Laud (2002)
	ZR75-1 and HTB-26		(+)	RT-PCR	Frankenberry (2006)
Mouse	4T1	(+)	(+)	IHC, WB, ELISA	Gonzalez et al. (2006), Gonzalez-Perez et al. (2010) and Zhou et al. (2011)
	EMT6	(+)	(+)	IHC, WB, ELISA	Gonzalez-Perez et al. (2010) and Zhou et al. (2011)
	MMT	(+)	(+)	IHC, WB, ELISA	Gonzalez-Perez et al. (2010) and Zhou et al. (2011)

^aDuctal invasive carcinoma.

^bCompared to no TNBC.

^cBasal level.